Key result
Nebivolol produces a ~3% smaller change in augmentation index than atenolol at 10 weeks.
Why the study?
Does nebivolol improve augmentation index compared to atenolol in patients with mild to moderate essential hypertension?
RCT (n=138)
double-blind
randomized
Yes
Does nebivolol improve augmentation index compared to atenolol in patients with mild to moderate essential hypertension?
In patients with mild to moderate hypertension, nebivolol produced a less pronounced impact on augmentation index compared to atenolol over 10 weeks.
Answers are grounded in this paper and cite their sources.
Nebivolol alters augmentation index less than atenolol; challenges assumptions of superior vascular effects for nebivolol in hypertension.
INTRODUCTION: The main objective was to compare the mean change in augmentation index of hypertensive patients treated with nebivolol or atenolol. METHODS: Multicenter, double-blind randomized study conducted in six Spanish centers. We enrolled outpatients between the ages of 40 and 65 years with mild or moderate essential hypertension (systolic blood pressure, SBP ≥ 140 mmHg to ≤ 179 mmHg and diastolic blood pressure, DBP ≥ 90 mmHg to ≤ 109 mmHg after a 2-week run-in placebo period). Patients received nebivolol 5 mg or atenolol 50 mg once daily. At week 3, atenolol could be titrated up to 100 mg qd for non-responders. Additionally, patients not achieving normal blood pressure after 6 weeks could be treated with 25 mg hydrochlorothiazide. Follow-up visits were at 3, 6 and 10 weeks. RESULTS: The final study population of 138 patients (58% men; median age 52.6 years, range 40-67 years) was randomized into two groups of 69 patients each. Baseline characteristics of the two groups were similar. At the screening visit, 69% presented with mild hypertension. Nebivolol modified the mean augmentation index to a lesser extent than atenolol after 10 weeks (mean difference 3.1%, 95% CI 0.55-5.69; p = 0.027). A higher proportion of patients in the atenolol group required a diuretic. Reductions in central aortic pressure and peripheral arterial pressure were similar for both treatment groups. CONCLUSIONS: The study confirms that nebivolol produces a less pronounced impact on augmentation index than atenolol.
No takes yet. Share an insight, caveat, or question.
Redón et al. (2013) conducted an RCT in mild or moderate essential hypertension (n=138). Nebivolol vs. Atenolol 50 mg once daily was evaluated on mean change in augmentation index (MD 3.1%, 95% CI 0.55-5.69, p=0.027). Nebivolol modified the mean augmentation index to a lesser extent than atenolol after 10 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: